Aminocaproic acid injection

This product is an antifibrinolytic drug. Fibrinogen specifically binds to fibrin through the lysine binding site in its molecular structure, and then turns into plasmin under the action of activators. This enzyme can cleave the arginine and lysine peptide chains in fibrin to form fibrin degradation products, which dissolve blood clots. The chemical structure of this product is similar to lysine, which can qualitatively inhibit the binding of plasminogen to fibrin and prevent its activation, thereby inhibiting fibrinolysis. High concentrations (100 mg/L) directly inhibit the activity of plasmin to achieve a hemostatic effect.

Chemical name: 6-aminocaproic acid. Structural formula: NH2(CH2)5COOH Molecular formula: C6H13NO2 Molecular weight: 131.17

This product is a colorless or almost colorless clear liquid.

It is suitable for the prevention and treatment of various bleeding caused by hyperfibrinolysis. ⑴ Bleeding caused by trauma or surgery in organs rich in plasminogen activators such as the prostate, urethra, lungs, liver, pancreas, brain, uterus, adrenal glands, thyroid glands, and bleeding caused by excessive tissue plasminogen activator (t-PA), streptokinase or urokinase. ⑵ Late stage of disseminated intravascular coagulation (DIC) to prevent secondary hyperfibrinolysis. ⑶ It can be used as an auxiliary treatment for bleeding after tooth extraction or oral surgery or menorrhagia in hemophilia patients. ⑷ It can be used for symptomatic treatment of various bleeding such as upper gastrointestinal bleeding, hemoptysis, idiopathic thrombocytopenic purpura and leukemia. It has a significant effect on general chronic oozing; it has poor efficacy on bleeding caused by abnormal coagulation function; it is effective for severe bleeding, heavy bleeding from wounds and bleeding from cancer, etc.

Because this product is excreted quickly, continuous administration is required to maintain effective concentration, so it is generally used for intravenous drip. The effective concentration of this product in vivo to inhibit fibrinolysis is at least 130 μg/ml. For patients with surgical bleeding or massive internal bleeding, rapid hemostasis requires rapid achievement of the above blood concentration. The initial amount can be 4-6g (20% solution) dissolved in 100ml of saline or 5-10% glucose solution, and dripped in 15-30 minutes. The continuous dose is 1g per hour, which can be taken orally or injected. Maintain for 12-24 hours or longer, depending on the condition.

1. This drug has certain side effects. As the dosage increases, the adverse reactions increase and the symptoms worsen. Moreover, the drug effect is short-lived and is now gradually used less and less. 2. Common adverse reactions are nausea, vomiting and diarrhea, followed by dizziness, itching, tinnitus, general discomfort, nasal congestion, rash, erythema, and no ejaculation. This is especially likely to occur when the daily dose exceeds 16g. Rapid intravenous injection may cause hypotension, tachycardia, arrhythmia, and a few people may have convulsions and heart or liver damage. Large doses or treatment courses of more than four weeks may cause myalgia, weakness, fatigue, myoglobinuria, and even renal failure, which can be relieved and recovered after drug discontinuation. 3. This product is excreted quickly in the urine with a high urine concentration. It can inhibit the fibrinolytic effect of urokinase, form blood clots, and block the urinary tract. Therefore, patients with hematuria after urology surgery should not take this drug.

1. Use with caution in patients with bleeding after urethral surgery; 2. Avoid use in patients with thrombotic tendency or past vascular embolism; 3. Use with caution in patients with renal insufficiency.

1. This product has a poor immediate hemostatic effect and should be used in combination with other hemostatic drugs for acute massive bleeding; 2. This product should not be mixed with hemostatics for injection.

Keep tightly closed.

20 ml: 4 g

Liaoning Xingao Pharmaceutical Co., Ltd.

• Founded in:

  2009-01-07

• Address:

  No. 8 Xiangzhang Road, Shiqiaozi, Xihu District, Benxi City

• Tax NO.:

  91210500683709405F

• Registered Funds:

  50 million yuan

• Email:

  Log in to view